Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib with R-ICE for R/R DLBCL
NCT02955628Phase 2Unknown
- Sponsor
- Singapore General Hospital
- Start
- Dec 2016
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Singapore General Hospital. Primary endpoint: Event-free survival at 3 years. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02955628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955628.